Cargando…

Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: Role of oxygenation status and tumour size

The urokinase plasminogen activator system plays a central role in malignant tumour progression. Both tumour hypoxia and enhancement of urokinase plasminogen activator, urokinase plasminogen activator-receptor and plasminogen activator inhibitor type 1 have been identified as adverse prognostic fact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weinmann, M, Thews, O, Schroeder, T, Vaupel, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375355/ https://www.ncbi.nlm.nih.gov/pubmed/11953898 http://dx.doi.org/10.1038/sj.bjc.6600237

Ejemplares similares

Nifedipine improves blood flow and oxygen supply, but not steady-state oxygenation of tumours in perfusion pressure-controlled isolated limb perfusion
por: Thews, O, et al.
Publicado: (2002)

Enhanced effects of aminolaevulinic acid-based photodynamic therapy through local hyperthermia in rat tumours
por: Kelleher, D K, et al.
Publicado: (2003)

Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment
por: Kelleher, D K, et al.
Publicado: (2003)

Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia
por: Thews, O, et al.
Publicado: (2004)

Downregulation of urokinase plasminogen activator receptor expression inhibits Erk signalling with concomitant suppression of invasiveness due to loss of uPAR–β1 integrin complex in colon cancer cells
por: Ahmed, N, et al.
Publicado: (2003)

Disparate responses of tumour vessels to angiotensin II: tumour volume-dependent effects on perfusion and oxygenation
por: Thews, O, et al.
Publicado: (2000)

Localized hypothermia: impact on oxygenation, microregional perfusion, metabolic and bioenergetic status of subcutaneous rat tumours.
por: Kelleher, D. K., et al.
Publicado: (1998)

Inhibition of urokinase plasminogen activator with a novel enzyme inhibitor, wxc-340, ameliorates endotoxin and surgery-accelerated growth of murine metastases
por: Killeen, S D, et al.
Publicado: (2007)

Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-dependent activation of the urokinase plasminogen activator system
por: Killeen, S D, et al.
Publicado: (2009)

Reduced blood flow and oxygenation in SA-1 tumours after electrochemotherapy with cisplatin
por: Sersa, G, et al.
Publicado: (2002)

Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
por: Seynhaeve, A L B, et al.
Publicado: (2002)

Preclinical studies of targeted α therapy for breast cancer using (213)Bi-labelled-plasminogen activator inhibitor type 2
por: Allen, B J, et al.
Publicado: (2003)

In silico docking of urokinase plasminogen activator and integrins
por: Degryse, Bernard, et al.
Publicado: (2008)

Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
por: Taubert, H, et al.
Publicado: (2010)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor
por: Albo, D, et al.
Publicado: (2000)

Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1–5
por: Hsieh, J-L, et al.
Publicado: (2003)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
por: Zhu, Ran, et al.
Publicado: (2022)

Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants
Publicado: (1989)

The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF)
por: Duverger, V, et al.
Publicado: (2004)

Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)
por: Magné, N, et al.
Publicado: (2002)

Localization of Urokinase‐type Plasminogen Activator, Plasminogen Activator Inhibitor‐1, 2 and Plasminogen in Colon Cancer
por: Naitoh, Hiroyuki, et al.
Publicado: (1995)

Invasion and MMP expression profile in desmoid tumours
por: Denys, H, et al.
Publicado: (2004)

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice
por: Ching, L-M, et al.
Publicado: (2004)

A modified p53 enhances apoptosis in sarcoma cell lines mediated by doxorubicin
por: Tang, H-J, et al.
Publicado: (2004)

Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors
Publicado: (1987)

Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
Publicado: (1984)

Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis
por: Kostourou, V, et al.
Publicado: (2002)

Secreted and tumour targeted human carboxylesterase for activation of irinotecan
por: Oosterhoff, D, et al.
Publicado: (2002)

Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis
por: Lee, Ji-Hye, et al.
Publicado: (2014)

Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer
por: Santin, A D, et al.
Publicado: (2002)

The plasminogen system and cell surfaces: evidence for plasminogen and urokinase receptors on the same cell type
Publicado: (1986)

Lack of efficacy of Doxil® in TNF-α-based isolated limb perfusion in sarcoma-bearing rats
por: ten Hagen, T L M, et al.
Publicado: (2004)

Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours.
por: Foucré, D., et al.
Publicado: (1991)

Zonal image analysis of tumour vascular perfusion, hypoxia, and necrosis
por: Fenton, B M, et al.
Publicado: (2002)

Stabilization of breast cancer xenograft tumour neovasculature by angiopoietin-1
por: Tian, S, et al.
Publicado: (2002)

Thiram inhibits angiogenesis and slows the development of experimental tumours in mice
por: Marikovsky, M
Publicado: (2002)

Effect of manipulation of primary tumour vascularity on metastasis in an adenocarcinoma model
por: Davies, M M, et al.
Publicado: (2002)

Ischaemia-reperfusion injury in photodynamic therapy-treated mouse tumours
por: Korbelik, M, et al.
Publicado: (2003)

Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth
por: Park, I-S, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_q6uuphgtvurqfm1li1veefb6m9